Existing user? Login

Product update

Decreased appetite with Exelon

Decreased appetite has been added to the list of undesirable effects in the summary of product characteristics (SPC) for Exelon (rivastigmine; Novartis). Additionally, the SPC now states that, on account of increased exposure in mild to moderate hepatic impairment as observed with the oral formulation, dosing recommendations to titrate according to individual tolerability should be closely followed. Patients with clinically significant hepatic impairment may experience more dose-dependent adverse reactions. Patients with severe hepatic impairment have not been studied and so particular caution should be exercised in titrating these patients.

Citation: Electronicjuice DOI: 10.1211/PJ.2015.20068522

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Electronicjuice, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

viagra 100